11th -13th September | Amsterdam

Main Conference Day 2

8:50 am - 9:00 am Chairman's Recap of Day One

9:00 am - 9:30 am The Value and Challenges of a Real World Data Strategy

Larry Pickett, Former VP & CEO,Purdue Pharma
  • Learn the key elements of an effective RWD strategy
  • Explore the roles of Stakeholders, Technology, Talent, & Partnerships
  • Review various approaches for a RWD programme in pharma with a case study
  • Discuss key use cases and challenges for RWD in pharma
  • Analyse how value can be expected from a RWD programme
img

Larry Pickett

Former VP & CEO
Purdue Pharma

9:45 am - 10:15 am CASE STUDY: Increasing Productivity by Utilising Real-World Data Evidence

Matt Wiener, Director, Data Science, IKU in EMEA,Celgene
  • Integrate RWD into your drug development process in order to bring new drugs to the market faster
  • Analyse the use of “synthetic control arms” of real world data to complement single-arm trials
  • Successfully implement RWD strategy in order to increase your ROI
img

Matt Wiener

Director, Data Science, IKU in EMEA
Celgene

10:15 am - 10:45 am From Data Science to Data Stories: Augmented Data Driven discovery and in-Silico R&D

Guido Smits, CSO,Datastories
  • Through technological breakthroughs, now even domain experts can apply AI and Machine Learning and augment their intelligence of the studied topic
  • Learn how our proprietary technology is crushing PCA accuracy and is able to determine the dominant variables out of even thousands and thousands of variables, like within genomics
  • Learn how in-silico design optimizes conflicting targets (eg. effectivity, stability and safety) boosting the performance of pharma development

img

Guido Smits

CSO
Datastories

10:45 am - 11:15 am Networking Coffee Break

11:15 am - 11:50 am ROUND TABLES: Gain Tangible Ideas on How to Solve Your Biggest Challenges

Find out what your peers are planning, share ideas and learn from others’ experiences in these open and informal discussions on how to solve
  • Internal collaboration
  • Collaboration with HCPs
  • How is Blockchain: Finance or Pharma
  • Business: The value story take by Silicon Valley is it too late?

11:50 am - 12:20 pm CASE STUDY: How to Utilise Data Analytics to Advance Personalised Medicine

David Whewell, Director of Architecture and Software Innovation,Merck Group
  • Develop a holistic environment for insight into better patient health outcomes
  • Grow an industry-wide visibility on clinical practices
  • Analyse new links between diseases and underlying symptoms, which are crucial in the chronic disease space
img

David Whewell

Director of Architecture and Software Innovation
Merck Group

12:20 pm - 1:20 pm Networking Lunch

1:20 pm - 1:50 pm CASE STUDY: Coordination and Optimisation of External Data Sources in the Drug Development Process

Mats Sundgren, Principal Scientist,AstraZeneca
  • Integrate external Electronic Health Information data with your legace data
  • Draw actionable insight and feeding data evidence into the drug developmental process
  • Utilise a combination of data sources to effectively structure your developmental strategy 
img

Mats Sundgren

Principal Scientist
AstraZeneca

1:50 pm - 2:20 pm The Post GDPR World of Data of Security and Transparency

Tarun Samtani, Group Data Privacy Lead – GDPR,Vectura Group plc.
  • Understand contract obligations under GDPR
  • Examine cyber security in Pharma
  • Analyse country specific regulatory exemption and compliance 
img

Tarun Samtani

Group Data Privacy Lead – GDPR
Vectura Group plc.

2:20 pm - 2:50 pm Networking Coffee Break

2:50 pm - 3:20 pm CASE STUDY: Liberating Real World Evidence from Federated Networks in Europe – What Have We Learned and Where are we Going?

Nigel Hughes, Scientific Director,Janssen
  • Analyse what we know now after  5 years of the IMI European Medical Information Framework (EMIF)
  • Look towards the IMI2 European Health Data and Evidence Network (EHDEN): what are we aiming for in 2023?
  • Investigate other federated initiatives and the EU health data ecosystem
img

Nigel Hughes

Scientific Director
Janssen

3:20 pm - 3:50 pm CASE STUDY: Coordination and Optimisation of External Data Sources in the Drug Development Process

John Mulcahy, Founder,HealthGenuity
  • Integrate external Electronic Health Information data with your legacy data
  • Draw actionable insight and feed data evidence into the drug developmental process
  • Utilise a combination of data sources to effectively structure your developmental strategy
img

John Mulcahy

Founder
HealthGenuity

3:50 pm - 4:05 pm Chairman's Reflection and Closing of Main Conference